Christopher Ryan Sullivan - Jan 28, 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Stock symbol
AVTX
Transactions as of
Jan 28, 2025
Transactions value $
$0
Form type
4
Date filed
1/30/2025, 05:43 PM
Previous filing
Aug 14, 2024
Next filing
Apr 1, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +163K $0.00 163K Jan 28, 2025 Common Stock 163K $8.04 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.